Sponsors / INBX
INBX

Inhibrx Biosciences, Inc

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
2Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of INBRX-109 in Conventional ChondrosarcomaNCT04950075INBXPhase 2Active not recruiting2025-09-30Actual
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCNCT06295731INBXPhase 2, Phase 3Active not recruiting2029-05Estimated

Latest recorded trial changes

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075 · Inhibrx Biosciences, Inc

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

201 participants (planned)

+ After

206 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Sep 2025

+ After

30 Sep 2025

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source